Published in N Engl J Med on January 01, 2014
Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral Density | NCT00896532
Study on the microRNA Expression Level in Postmenopausal Osteoporosis (microRNA) | NCT02128009
HDAC5 controls MEF2C-driven sclerostin expression in osteocytes. J Bone Miner Res (2015) 1.60
Fracture healing: mechanisms and interventions. Nat Rev Rheumatol (2014) 1.33
Antibodies to watch in 2015. MAbs (2015) 1.28
Romosozumab in postmenopausal women with osteopenia. N Engl J Med (2014) 1.18
Osteoclasts: more than 'bone eaters'. Trends Mol Med (2014) 1.17
Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol (2015) 1.15
Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol (2015) 0.98
Mechanical load increases in bone formation via a sclerostin-independent pathway. J Bone Miner Res (2014) 0.95
Wnts produced by Osterix-expressing osteolineage cells regulate their proliferation and differentiation. Proc Natl Acad Sci U S A (2014) 0.94
Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone (2014) 0.94
Sclerostin Inhibition in the Management of Osteoporosis. Calcif Tissue Int (2016) 0.92
Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model. FASEB J (2015) 0.92
A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat Rev Rheumatol (2015) 0.90
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci U S A (2014) 0.90
Bone biology and anabolic therapies for bone: current status and future prospects. J Bone Metab (2014) 0.90
Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int (2015) 0.89
From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol (2015) 0.89
Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype. J Osteoporos (2015) 0.88
Wnt signaling and osteoporosis. Maturitas (2014) 0.88
Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int (2015) 0.87
Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporos Int (2014) 0.87
Romosozumab in postmenopausal women with osteopenia. N Engl J Med (2014) 0.86
Biological agents in management of osteoporosis. Eur J Clin Pharmacol (2014) 0.86
Inhaled corticosteroids and bone health. Open Respir Med J (2014) 0.86
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis (2016) 0.86
Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis. Front Endocrinol (Lausanne) (2015) 0.84
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. Int J Womens Health (2015) 0.83
Effect of osteoporosis medications on fracture healing. Osteoporos Int (2015) 0.83
Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta. J Bone Miner Res (2016) 0.82
Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort. Sci Rep (2016) 0.82
Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro. Bonekey Rep (2015) 0.82
Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast Cancer Res (2014) 0.82
Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int (2015) 0.82
Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age. Bone (2016) 0.82
Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing. PLoS One (2015) 0.81
Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis. Drugs (2015) 0.81
Sclerostin inhibition for osteoporosis--a new approach. N Engl J Med (2014) 0.81
Male Osteoporosis in the Elderly. Int J Endocrinol (2015) 0.81
Protective alleles and modifier variants in human health and disease. Nat Rev Genet (2015) 0.81
PTH1-34 blocks radiation-induced osteoblast apoptosis by enhancing DNA repair through canonical Wnt pathway. J Biol Chem (2014) 0.80
Osteocytic signalling pathways as therapeutic targets for bone fragility. Nat Rev Endocrinol (2016) 0.80
Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers. Clin J Am Soc Nephrol (2014) 0.80
Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton. Osteoporos Int (2014) 0.80
Recent developments in osteogenesis imperfecta. F1000Res (2015) 0.80
Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol (2015) 0.80
Osteochemonecrosis: an overview. Head Neck Pathol (2014) 0.79
Transcriptional profiling of cortical versus cancellous bone from mechanically-loaded murine tibiae reveals differential gene expression. Bone (2016) 0.79
New horizons in treatment of osteoporosis. Daru (2017) 0.79
Bisphosphonates and glucocorticoid-induced osteoporosis: cons. Endocrine (2015) 0.78
Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy. J Biol Chem (2015) 0.78
Role and mechanism of action of sclerostin in bone. Bone (2016) 0.78
Inhibitors of sclerostin: emerging concepts. Curr Opin Rheumatol (2014) 0.78
LRP receptor family member associated bone disease. Rev Endocr Metab Disord (2015) 0.78
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun (2016) 0.78
Osteocyte specific responses to soluble and mechanical stimuli in a stem cell derived culture model. Sci Rep (2015) 0.78
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats. Sci Rep (2015) 0.78
Genome-Wide Mapping and Interrogation of the Nmp4 Antianabolic Bone Axis. Mol Endocrinol (2015) 0.77
Chronic kidney disease and bone metabolism. J Bone Miner Metab (2015) 0.77
Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse. Bone (2016) 0.77
Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases. J Bone Miner Res (2015) 0.77
Revisiting the role of Wnt/β-catenin signaling in prostate cancer. Mol Cell Endocrinol (2017) 0.77
Anabolic actions of Notch on mature bone. Proc Natl Acad Sci U S A (2016) 0.76
Smad4 is required to inhibit osteoclastogenesis and maintain bone mass. Sci Rep (2016) 0.76
Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. J Osteoporos (2016) 0.76
New insights into treatment of osteoporosis in postmenopausal women. RMD Open (2015) 0.76
Endocrinology research-reflecting on the past decade and looking to the next. Nat Rev Endocrinol (2015) 0.76
Connecting the Dots: Linking Osteocyte Activity and Therapeutic Modulation of Sclerostin by Extending a Multiscale Systems Model. CPT Pharmacometrics Syst Pharmacol (2015) 0.76
From disease to treatment: from rare skeletal disorders to treatments for osteoporosis. Endocrine (2016) 0.76
A comprehensive study of long-term skeletal changes after spinal cord injury in adult rats. Bone Res (2015) 0.76
Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations. Bonekey Rep (2014) 0.76
Bone repair with skeletal stem cells: rationale, progress to date and clinical application. Ther Adv Musculoskelet Dis (2016) 0.76
Sclerostin Antibody Administration Converts Bone Lining Cells into Active Osteoblasts. J Bone Miner Res (2016) 0.76
The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos Int (2016) 0.76
The Skeletal Cell-Derived Molecule Sclerostin Drives Bone Marrow Adipogenesis. J Cell Physiol (2017) 0.75
Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy. AIDS Res Hum Retroviruses (2015) 0.75
Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression. BMC Musculoskelet Disord (2015) 0.75
Hormonal and systemic regulation of sclerostin. Bone (2016) 0.75
Transient Canonical Wnt Stimulation Enriches Human Bone Marrow Mononuclear Cell Isolates for Osteoprogenitors. Stem Cells (2015) 0.75
Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman With Systemic Lupus Erythematosus. J Bone Miner Res (2016) 0.75
Emerging Therapies for Osteoporosis. Endocrinol Metab (Seoul) (2015) 0.75
Serum Sema4D levels are associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis. Int J Clin Exp Med (2015) 0.75
A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis. Calcif Tissue Int (2016) 0.75
CORR Insights(®): Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model? Clin Orthop Relat Res (2016) 0.75
Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model. Bone (2016) 0.75
Anorexia nervosa and bone metabolism. Bone (2014) 0.75
The best of both worlds - managing the cancer, saving the bone. Nat Rev Endocrinol (2015) 0.75
Modeling craniofacial and skeletal congenital birth defects to advance therapies. Hum Mol Genet (2016) 0.75
Value of rare low bone mass diseases for osteoporosis genetics. Bonekey Rep (2016) 0.75
Pharmacotherapy: Novel antibody therapy demonstrates potential for building bone in osteoporosis. Nat Rev Endocrinol (2014) 0.75
Osteoporosis therapeutics: recent developments at ASBMR. Ther Adv Musculoskelet Dis (2016) 0.75
SIKs control osteocyte responses to parathyroid hormone. Nat Commun (2016) 0.75
Novel therapeutic targets in myeloma bone disease. Br J Pharmacol (2014) 0.75
Novel advances in the treatment of osteoporosis. Br Med Bull (2016) 0.75
Clec11a/osteolectin is an osteogenic growth factor that promotes the maintenance of the adult skeleton. Elife (2016) 0.75
Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo. Mol Ther Nucleic Acids (2016) 0.75
New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide. Bone Res (2014) 0.75
PDGFB-based stem cell gene therapy increases bone strength in the mouse. Proc Natl Acad Sci U S A (2015) 0.75
Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease. Curr Opin Nephrol Hypertens (2016) 0.75
Relevance of Wnt signaling for osteoanabolic therapy. Mol Cell Ther (2014) 0.75
Application of anti-Sclerostin therapy in non-osteoporosis disease models. Bone (2016) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med (2007) 7.60
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am (2004) 7.59
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med (2010) 6.13
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 4.63
Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med (2010) 4.24
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med (2014) 4.14
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol (2008) 3.68
Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab (2008) 3.67
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med (2003) 3.07
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet (2002) 3.00
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med (2006) 2.74
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68
The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell (2004) 2.65
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J (2007) 2.59
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. J Bone Miner Res (2015) 2.52
Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA (2008) 2.52
Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: a randomized controlled pilot study. J Bone Miner Res (2003) 2.47
A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res (2012) 2.43
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab (2008) 2.43
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol (2011) 2.28
Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res (2004) 2.21
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res (2010) 2.20
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum (2009) 2.16
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol (2009) 2.11
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res (2011) 2.07
Androgens and bone. Endocr Rev (2004) 2.06
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab (2010) 2.01
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA (2012) 1.99
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone (2007) 1.94
The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol (2006) 1.93
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2007) 1.92
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol (2012) 1.88
HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. J Bone Miner Res (2013) 1.84
The tissue diagnostic instrument. Rev Sci Instrum (2009) 1.82
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 1.82
Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab (2011) 1.81
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2014) 1.78
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res (2008) 1.78
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res (2012) 1.77
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74
The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther (2005) 1.72
Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study. PLoS Med (2006) 1.68
Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res (2013) 1.66